Transformation to Inducible Pluripotent Stem Cells

Kazuki Kodo, Sang Ging Ong, Joseph C. Wu

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Since the discovery of embryonic stem cells (ESCs) in 1981, they have been used as a gold standard for stem cell therapy. However, the generation of ESCs requires the destruction of an embryo, making the use of these cells ethically controversial. ESC therapy is also hampered by immune rejection of ESC-derived allografts. In 2006, Shinya Yamanaka and colleagues developed an innovative protocol whereby somatic cells could be reprogrammed and dedifferentiated into a pluripotent state by transduction of four transcription factors, providing scientists with an alternative to overcome the ethical and immune rejection issues posed by ESCs. Since the breakthrough, numerous groups have developed various protocols to generate these induced pluripotent stem cells (iPSCs). However, the original protocol used to generate iPSCs involves the use of retrovirus, which can lead to genomic integration of virus genome into the host genome and can be a potential obstacle for future clinical translation of iPSC-based regenerative medicine. Recent rapid development of this field has introduced modified protocols to generate iPSCs using non-integrative techniques with increasing efficiency. These new developments have brought us one step closer to developing a safe and efficient method to reprogram cells for clinical use and shall be discussed in this chapter.

Original languageEnglish
Title of host publicationStem Cell and Gene Therapy for Cardiovascular Disease
PublisherElsevier Science Ltd.
Pages243-265
Number of pages23
ISBN (Electronic)9780128018637
ISBN (Print)9780128018880
DOIs
Publication statusPublished - 2015 Jan 1
Externally publishedYes

Fingerprint

Pluripotent Stem Cells
Embryonic Stem Cells
Induced Pluripotent Stem Cells
Cell- and Tissue-Based Therapy
Genome
Virus Integration
Regenerative Medicine
Retroviridae
Allografts
Transcription Factors
Stem Cells
Embryonic Structures

Keywords

  • Disease modeling
  • Immunogenicity
  • Induced pluripotent stem cell derived cardiomyocytes
  • Stem cell therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kodo, K., Ong, S. G., & Wu, J. C. (2015). Transformation to Inducible Pluripotent Stem Cells. In Stem Cell and Gene Therapy for Cardiovascular Disease (pp. 243-265). Elsevier Science Ltd.. https://doi.org/10.1016/B978-0-12-801888-0.00020-5

Transformation to Inducible Pluripotent Stem Cells. / Kodo, Kazuki; Ong, Sang Ging; Wu, Joseph C.

Stem Cell and Gene Therapy for Cardiovascular Disease. Elsevier Science Ltd., 2015. p. 243-265.

Research output: Chapter in Book/Report/Conference proceedingChapter

Kodo, K, Ong, SG & Wu, JC 2015, Transformation to Inducible Pluripotent Stem Cells. in Stem Cell and Gene Therapy for Cardiovascular Disease. Elsevier Science Ltd., pp. 243-265. https://doi.org/10.1016/B978-0-12-801888-0.00020-5
Kodo K, Ong SG, Wu JC. Transformation to Inducible Pluripotent Stem Cells. In Stem Cell and Gene Therapy for Cardiovascular Disease. Elsevier Science Ltd. 2015. p. 243-265 https://doi.org/10.1016/B978-0-12-801888-0.00020-5
Kodo, Kazuki ; Ong, Sang Ging ; Wu, Joseph C. / Transformation to Inducible Pluripotent Stem Cells. Stem Cell and Gene Therapy for Cardiovascular Disease. Elsevier Science Ltd., 2015. pp. 243-265
@inbook{cca02831c9d14660a3e95a5621acb135,
title = "Transformation to Inducible Pluripotent Stem Cells",
abstract = "Since the discovery of embryonic stem cells (ESCs) in 1981, they have been used as a gold standard for stem cell therapy. However, the generation of ESCs requires the destruction of an embryo, making the use of these cells ethically controversial. ESC therapy is also hampered by immune rejection of ESC-derived allografts. In 2006, Shinya Yamanaka and colleagues developed an innovative protocol whereby somatic cells could be reprogrammed and dedifferentiated into a pluripotent state by transduction of four transcription factors, providing scientists with an alternative to overcome the ethical and immune rejection issues posed by ESCs. Since the breakthrough, numerous groups have developed various protocols to generate these induced pluripotent stem cells (iPSCs). However, the original protocol used to generate iPSCs involves the use of retrovirus, which can lead to genomic integration of virus genome into the host genome and can be a potential obstacle for future clinical translation of iPSC-based regenerative medicine. Recent rapid development of this field has introduced modified protocols to generate iPSCs using non-integrative techniques with increasing efficiency. These new developments have brought us one step closer to developing a safe and efficient method to reprogram cells for clinical use and shall be discussed in this chapter.",
keywords = "Disease modeling, Immunogenicity, Induced pluripotent stem cell derived cardiomyocytes, Stem cell therapy",
author = "Kazuki Kodo and Ong, {Sang Ging} and Wu, {Joseph C.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/B978-0-12-801888-0.00020-5",
language = "English",
isbn = "9780128018880",
pages = "243--265",
booktitle = "Stem Cell and Gene Therapy for Cardiovascular Disease",
publisher = "Elsevier Science Ltd.",

}

TY - CHAP

T1 - Transformation to Inducible Pluripotent Stem Cells

AU - Kodo, Kazuki

AU - Ong, Sang Ging

AU - Wu, Joseph C.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Since the discovery of embryonic stem cells (ESCs) in 1981, they have been used as a gold standard for stem cell therapy. However, the generation of ESCs requires the destruction of an embryo, making the use of these cells ethically controversial. ESC therapy is also hampered by immune rejection of ESC-derived allografts. In 2006, Shinya Yamanaka and colleagues developed an innovative protocol whereby somatic cells could be reprogrammed and dedifferentiated into a pluripotent state by transduction of four transcription factors, providing scientists with an alternative to overcome the ethical and immune rejection issues posed by ESCs. Since the breakthrough, numerous groups have developed various protocols to generate these induced pluripotent stem cells (iPSCs). However, the original protocol used to generate iPSCs involves the use of retrovirus, which can lead to genomic integration of virus genome into the host genome and can be a potential obstacle for future clinical translation of iPSC-based regenerative medicine. Recent rapid development of this field has introduced modified protocols to generate iPSCs using non-integrative techniques with increasing efficiency. These new developments have brought us one step closer to developing a safe and efficient method to reprogram cells for clinical use and shall be discussed in this chapter.

AB - Since the discovery of embryonic stem cells (ESCs) in 1981, they have been used as a gold standard for stem cell therapy. However, the generation of ESCs requires the destruction of an embryo, making the use of these cells ethically controversial. ESC therapy is also hampered by immune rejection of ESC-derived allografts. In 2006, Shinya Yamanaka and colleagues developed an innovative protocol whereby somatic cells could be reprogrammed and dedifferentiated into a pluripotent state by transduction of four transcription factors, providing scientists with an alternative to overcome the ethical and immune rejection issues posed by ESCs. Since the breakthrough, numerous groups have developed various protocols to generate these induced pluripotent stem cells (iPSCs). However, the original protocol used to generate iPSCs involves the use of retrovirus, which can lead to genomic integration of virus genome into the host genome and can be a potential obstacle for future clinical translation of iPSC-based regenerative medicine. Recent rapid development of this field has introduced modified protocols to generate iPSCs using non-integrative techniques with increasing efficiency. These new developments have brought us one step closer to developing a safe and efficient method to reprogram cells for clinical use and shall be discussed in this chapter.

KW - Disease modeling

KW - Immunogenicity

KW - Induced pluripotent stem cell derived cardiomyocytes

KW - Stem cell therapy

UR - http://www.scopus.com/inward/record.url?scp=85072149787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072149787&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-801888-0.00020-5

DO - 10.1016/B978-0-12-801888-0.00020-5

M3 - Chapter

AN - SCOPUS:85072149787

SN - 9780128018880

SP - 243

EP - 265

BT - Stem Cell and Gene Therapy for Cardiovascular Disease

PB - Elsevier Science Ltd.

ER -